Improvement in prostate cancer survival over time: a 20-year analysis [0.03%]
前列腺癌生存率的长期变化趋势——20年的分析结果
Michelle M Kim,Karen E Hoffman,Lawrence B Levy et al.
Michelle M Kim et al.
Purpose: This study aimed to evaluate the changes in outcome for men with localized prostate cancer treated with definitive external beam radiation therapy during a 20-year period at a comprehensive cancer center. ...
David A Fenstermacher,Robert M Wenham,Dana E Rollison et al.
David A Fenstermacher et al.
In 2006, the Moffitt Cancer Center partnered with patients, community clinicians, industry, academia, and 17 hospitals in the United States to begin a personalized cancer care initiative called Total Cancer Care. Total Cancer Care was desig...
Jill E Larsen,Tina Cascone,David E Gerber et al.
Jill E Larsen et al.
Although lung cancer remains the leading cancer killer in the United States, recently a number of developments indicate future clinical benefit. These include evidence that computed tomography-based screening decreases lung cancer mortality...
Keith T Flaherty
Keith T Flaherty
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very r...
Seong-Rim Kim,Soonmyung Paik
Seong-Rim Kim
Therapeutic decision for adjuvant systemic therapy for breast cancer involves assessment of baseline risk and estimated benefit from systemic therapy. Molecular profiling studies have clearly demonstrated heterogeneity of chemotherapy respo...
Karen Lisa Smith,Claudine Isaacs
Karen Lisa Smith
BRCA mutation-associated breast cancer differs from sporadic breast cancer with regard to future cancer risks and sensitivity to systemic therapies. Now that rapid genetic testing for BRCA1 and BRCA2 mutations is available at the time of br...
Timothy A Graubert,Elaine R Mardis
Timothy A Graubert
The acute myeloid leukemia (AML) genome has been the subject of intensive research over the past 4 decades. New technologies, enabling characterization of the AML genome at increased resolution, have revealed deeper layers of complexity tha...
David W Woessner,Carol S Lim,Michael W Deininger
David W Woessner
Targeted small-molecule drugs have revolutionized treatment of chronic myeloid leukemia (CML) during the last decade. These agents interrupt a constitutively active BCR-ABL, the causative agent for CML, by interfering with adenosine 5' trip...
Fabio P S Santos,Hagop Kantarjian,Alfonso Quintás-Cardama et al.
Fabio P S Santos et al.
The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the o...
Emerging technologies for improved stratification of cancer patients: a review of opportunities, challenges, and tools [0.03%]
癌症患者分类技术改进的新兴科技:机遇、挑战及工具综述
Wisut Lamlertthon,Michele C Hayward,David Neil Hayes
Wisut Lamlertthon
Cancer is a heterogeneous collection of diseases with wild variation in etiology, pathogenesis, response to therapy, and prognosis. Sources of variation are frequently obscure. Current practice attempts to classify tumors by tissue of origi...